The relationship between pediatric combination vaccines and market effects.

Abstract

We explored market factors that affect pediatric combination vaccine uptake in the US public-sector pediatric vaccine market. We specifically examined how Pediarix and Pentacel earned a place in the 2009-2012 lowest overall cost formulary. Direct competition between Pediarix and Pentacel is driven by the indirect presence of the Merck Haemophilus influenzae type b vaccine and the Recommended Childhood Immunization Schedule requirement for a hepatitis B birth dose. The resulting analysis suggests that Pentacel would never have earned a place in the lowest overall cost formulary for 2009-2012 federal contract prices for any cost of an injection unless the Merck H influenzae type b advantage was ignored and the hepatitis B birth dose administration cost was recognized by health care providers in designing the lowest overall cost formularies.

• Authors: Banafsheh Behzad, Sheldon H Jacobson, Janet A Jokela, Edward C Sewell
• Journal: American journal of public health (Am J Public Health) Vol. 104 Issue 6 Pg. 998-1004 (Jun 2014) ISSN: 1541-0048 [Electronic] United States
• PMID: 24825198 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Diphtheria-Tetanus-Pertussis Vaccine
• Haemophilus Vaccines
• Hepatitis B Vaccines
• PEDIARIX
• Poliovirus Vaccine, Inactivated
• Vaccines, Combined
• pentacel

Topics

• Child
• Child, Preschool
• Diphtheria-Tetanus-Pertussis Vaccine (economics, therapeutic use)
• Drug Costs
• Drug Industry (economics)
• Haemophilus Vaccines (economics, therapeutic use)
• Hepatitis B Vaccines (economics, therapeutic use)
• Humans
• Immunization Programs (economics)
• Infant
• Infant, Newborn
• Poliovirus Vaccine, Inactivated (economics, therapeutic use)
• United States
• Vaccines, Combined (economics, therapeutic use)